41
views
0
recommends
+1 Recommend
3 collections
    1
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Pediatric Endocrinology in the Time of COVID-19: Considerations for the Rapid Implementation of Telemedicine and Management of Pediatric Endocrine Conditions

      review-article

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Pediatric endocrine practices had to rapidly transition to telemedicine care at the onset of the novel coronavirus disease 2019 (COVID-19) pandemic. For many, it was an abrupt introduction to providing virtual healthcare, with concerns related to quality of patient care, patient privacy, productivity, and compensation, as workflows had to change. Summary: The review summarizes the common adaptations for telemedicine during the pandemic with respect to the practice of pediatric endocrinology and discusses the benefits and potential barriers to telemedicine. Key Messages: With adjustments to practice, telemedicine has allowed providers to deliver care to their patients during the COVID-19 pandemic. The broader implementation of telemedicine in pediatric endocrinology practice has the potential for expanding patient access. Research assessing the impact of telemedicine on patient care outcomes in those with pediatric endocrinology conditions will be necessary to justify its continued use beyond the COVID-19 pandemic.

          Related collections

          Most cited references76

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents

          These pediatric hypertension guidelines are an update to the 2004 "Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents." Significant changes in these guidelines include (1) the replacement of the term "prehypertension" with the term "elevated blood pressure," (2) new normative pediatric blood pressure (BP) tables based on normal-weight children, (3) a simplified screening table for identifying BPs needing further evaluation, (4) a simplified BP classification in adolescents ≥13 years of age that aligns with the forthcoming American Heart Association and American College of Cardiology adult BP guidelines, (5) a more limited recommendation to perform screening BP measurements only at preventive care visits, (6) streamlined recommendations on the initial evaluation and management of abnormal BPs, (7) an expanded role for ambulatory BP monitoring in the diagnosis and management of pediatric hypertension, and (8) revised recommendations on when to perform echocardiography in the evaluation of newly diagnosed hypertensive pediatric patients (generally only before medication initiation), along with a revised definition of left ventricular hypertrophy. These guidelines include 30 Key Action Statements and 27 additional recommendations derived from a comprehensive review of almost 15 000 published articles between January 2004 and July 2016. Each Key Action Statement includes level of evidence, benefit-harm relationship, and strength of recommendation. This clinical practice guideline, endorsed by the American Heart Association, is intended to foster a patient- and family-centered approach to care, reduce unnecessary and costly medical interventions, improve patient diagnoses and outcomes, support implementation, and provide direction for future research.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline

            To update the "Endocrine Treatment of Transsexual Persons: An Endocrine Society Clinical Practice Guideline," published by the Endocrine Society in 2009.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline

              To update the congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency clinical practice guideline published by the Endocrine Society in 2010.
                Bookmark

                Author and article information

                Journal
                HRP
                Horm Res Paediatr
                10.1159/issn.1663-2818
                Hormone Research in Paediatrics
                S. Karger AG
                1663-2818
                1663-2826
                2020
                22 January 2021
                : 93
                : 6
                : 343-350
                Affiliations
                [_a] aDivision of Pediatric Endocrinology and Diabetes, Children’s Hospital at Montefiore, Albert Einstein School of Medicine, Bronx, New York, USA
                [_b] bDivision of Pediatric Endocrinology, Baystate Children’s Hospital, Springfield, Massachusetts, USA
                [_c] cDivision of Pediatric Endocrinology, Georgetown University, Washington, District of Columbia, USA
                [_d] dDivision of Pediatric Endocrinology, Diabetes and Metabolism, Children’s Hospital of Richmond at Virginia Commonwealth University, Richmond, Virginia, USA
                [_e] eDivision of Pediatric Endocrinology, Department of Pediatrics, OHSU (Oregon Health and Science University), Portland, Oregon, USA
                [_f] fCenter for Diabetes and Endocrinology, Department of Pediatrics, Akron Children’s Hospital, Akron, Ohio, USA
                [_g] gDivision of Pediatric Endocrinology, Nationwide Children’s Hospital at The Ohio State University, Columbus, Ohio, USA
                [_h] hDivision of Pediatric Diabetes and Endocrinology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA
                [_i] iDivision of Endocrinology, Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee, USA
                [_j] jDivision of Pediatric Endocrinology, Medical University of South Carolina, Charleston, South Carolina, USA
                Author notes
                *Molly O. Regelmann, Division of Pediatric Endocrinology, Children’s Hospital at Montefiore, 3415 Bainbridge Ave., Bronx NY 10467 (USA), moregelm@montefiore.org
                Article
                513060 Horm Res Paediatr
                10.1159/000513060
                33486483
                83eb7dd6-ba91-4660-9949-23dd660bd302
                © 2021 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                : 24 September 2020
                : 14 November 2020
                Page count
                Tables: 3, Pages: 8
                Categories
                Clinical Practice Committee Publication

                Internal medicine,Respiratory medicine,Clinical Psychology & Psychiatry,Microbiology & Virology,Infectious disease & Microbiology
                Pediatric endocrinology,Diabetes,Telemedicine,Coronavirus disease 2019

                Comments

                Comment on this article